DCAF8L1 and breast carcinoma: To investigate whether DACF8L1-mediated regulation of BRCA1 could also affect sensitivity to PARPi, MCF10A cell line stably overexpressing DCAF8L1 was generated and treated with Olaparib, one of the PARPis used for the treatment of BRCA1-deficient breast cancers in the clinics.